Analyst Ratings for Eli Lilly (LLY) [Buys]
LLY Rating Summary
LLY Price Target Summary
- Highest: $59.50 (Leerink Swann)
- Lowest: $37.00 (BMO Capital)
- Average: $48.14
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$48.14 (-11.1%)
Avg. $ Target:
$48.14 (-11.1%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 11/30/2012 | Citi | New Coverage | Buy (N/A) |
55.00 (N/A) |
48.58 | 54.14 | 11.45% | Details |
| 10/15/2012 | Leerink Swann | Upgrade | Outperform (Market Perform) |
59.50 (52.00) |
50.45 | 54.14 | 7.31% | Details |
| 9/5/2012 | Bernstein | Upgrade | Outperform (Market Perform) |
52.00 (46.00) |
45.29 | 54.14 | 19.54% | Details |
| 8/28/2012 | Atlantic Equities | Upgrade | Overweight (Underweight) |
N/A (N/A) |
44.59 | 54.14 | 21.42% | Details |
| 8/24/2012 | Credit Suisse | Upgrade | Outperform (Neutral) |
N/A (N/A) |
42.40 | 54.14 | 27.69% | Details |
| 10/28/2011 | First Global | Upgrade | Moderate Outperform (N/A) |
N/A (N/A) |
37.87 | 54.14 | 42.96% | Details |
| 8/10/2011 | Argus | Upgrade | Buy (N/A) |
N/A (N/A) |
35.64 | 54.14 | 51.91% | Details |
| 4/19/2011 | Hapoalim Securities | Upgrade | Buy (N/A) |
N/A (N/A) |
35.62 | 54.14 | 51.99% | Details |
